The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis

The National Cancer Institute (NCI) estimates that over 2 million Americans will be diagnosed with cancer in 2025. A significant proportion of these patients will receive chemotherapeutics, radiation, molecularly targeted therapies, or immunotherapies-many of which are associated with pulmonary toxicity. Drug-induced interstitial lung disease (D-ILD) is a growing and well-recognized complication of cancer-related therapies, carrying substantial morbidity and mortality. In addition to its direct health impact, D-ILD often necessitates modification or discontinuation of cancer treatment, further complicating oncologic care. As such, pulmonologists must be proficient in the evaluation and management of suspected D-ILD. In this review, we propose a structured approach to assessing patients with malignancy who present with diffuse parenchymal lung disease. We also summarize commonly implicated cancer therapies and their associated pulmonary toxicities.